That’s why I hope that the presentation 25th will put that doubt to rest.
The possibility of misdiagnosis and no placebo control in a small trial is good reason why the market so far is not too impressed.
The science and totally of information that we are all aware of is why I see Anavex as one the best risk/reward ratios I know of at present. Getting into an Anavex position in 6 months to 2 years from now could turn out significantly more expensive.
I sometimes have concerns that the six were misdiagnosed as well. Then I remember that all signed up, not just super responders, for the extension. And Dr Macfarlane sounds very positive.
We are all on pins and needles wondering what will be presented next week... More data from extended trial? Biomarker data implications? Additional data mining from current data and the above? More rwe info?
Could be could be just one more step forward for science or could be HUGE BLOCKBUSTERS!
Either way the science will be out there. The word will start to spread.
Second step climbing the mountain for us or a huge second step.
Market Data 
Markets 
